Please use this identifier to cite or link to this item:
Title: The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
Austin Authors: Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia
Issue Date: 3-Jul-2014
Publication information: Oncoimmunology 2014; 3(7): e946367
Abstract: Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.
Gov't Doc #: 25610732
DOI: 10.4161/21624011.2014.946367
Journal: Oncoimmunology
Type: Journal Article
Subjects: BRAF
dendritic cells
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 30, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.